Wim brings more than 40 years of experience in strategic financial roles, raising close to €1billion for multiple biotech companies across various markets. He successfully brought private companies to public markets in Europe (Euronext) and the U.S.A. (Nasdaq) and has a broad and global network of investors and financial institutions.
Prior to joining Biotalys, until September 2018, he was Chief Financial Officer of Ablynx, a leading Belgian biotech company that was listed on Euronext Brussels and Nasdaq until its acquisition by Sanofi in June 2018 for €3.9 billion. Before that, he was Chief Financial Officer of Innogenetics (now Fujirebio Europe), a biotech company listed on Euronext Brussels at that time. Wim has held various positions in finance and administration prior to joining Innogenetics and is currently non-executive director for several biotech companies. Wim holds a Master’s degree in Business Economics from the University of Antwerp, Belgium.